The cover story of the June issue of CAP TODAY summarized the findings of a research study recently published in the New England Journal of Medicine titled, Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Interviewed for the CAP TODAY article, With AML genetic profiling, it takes all kinds, were two of the study's coauthors and Mayo Clinic physicians, Mark Litzow, M.D., and Rhett Ketterling, M.D. Dr. Litzow is a hematologist at Mayo Clinic and Dr. Ketterling is a pathologist and codirector of the Mayo Clinic Cytogenetics Laboratory.
According to CAP TODAY, "The phase three clinical trial, E1900, provides the most nuanced view of AML genetic profiles to date, with researchers performing a mutational analysis of 18 genes in 398 AML patients under age 60."
Drs. Litzow and Ketterling were among 31 authors of the study by the Eastern Cooperative Oncology Group.
For your reference, links to the CAP TODAY and New England Journal of Medicine articles have been included below.